Levers impacting access to prostate cancer treatment are very different in the US to the EU and the UK.
Download your complimentary prostate cancer infographic and discover:
Payer archetypes and trends in access
Least restrictive: US
Relatively unrestricted: France and Germany
Restrictive: Italian and Spanish regions
Most restrictive: UK
National Institute for Health and Care Excellence (NICE) applies arguably the most stringent cost-effectiveness analyses of any European nation
Levers impacting access to prostate cancer drugs in the US:
Insurers’ prior authorization criteria
Formulary tiering and patient co-pays
Levers impacting access to prostate cancer drugs in the five major EU markets:
National reimbursement decisions
Regional or local access criteria
Off-label prescribing controls
Why Zytiga favored over Xtandi on Anthem’s oncology pathway?
What Medicare’s shift to value-based payment means
The rebates and risk-sharing agreements that will be valuable in non-metastatic CRPC
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: